Xilio Therapeutics, INC. 8-K Filing
Ticker: XLO · Form: 8-K · Filed: Nov 25, 2025 · CIK: 1840233
Sentiment: neutral
Filing Stats: 939 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2025-11-25 16:05:26
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share XLO Nasdaq Capital Market
- $1.50 — foregoing stock options was reduced to $1.50 per share. If a repriced stock option i
Filing Documents
- xlo-20251121.htm (8-K) — 114KB
- 0001193125-25-297165.txt ( ) — 232KB
- xlo-20251121.xsd (EX-101.SCH) — 31KB
- xlo-20251121_htm.xml (XML) — 5KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On November 21, 2025, the Company held the Special Meeting. The following is a summary of the matters voted on at that meeting and the results of the votes on such matters.. 1. The Company's stockholders approved a one-time repricing of certain outstanding employee stock options ("Proposal 1"). The results of the stockholders' vote with respect to such approval were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 31,600,793 1,690,846 144,025 0 2. The Company's stockholders approved the 2025 Plan ("Proposal 2"). The results of the stockholders' vote with respect to such approval were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 30,542,811 2,876,155 16,698 0 3. The Company's stockholders approved the proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal 1 and/or Proposal 2. The results of the stockholders' vote with respect to such approval were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 30,757,060 2,635,979 42,625 0
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (incorporated by reference to Appendix A of the Registrant's DEF 14A (File 001-40925) filed with the Securities and Exchange Commission on October 20, 2025). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XILIO THERAPEUTICS, INC. Date: November 25, 2025 By: /s/ Caroline Hensley Caroline Hensley Chief Legal Officer